IP Library Assignment 056171/0666
Patent Assignment
Reel/Frame 056171/0666

Change of Name

Recorded: 2021-05-06 Pages: 6
Assignor
GRITSTONE ONCOLOGY, INC.
Executed: 2021-05-03
Assignee
GRITSTONE BIO, INC.
5959 HORTON STREET, EMERYVILLE, CALIFORNIA, 94608
Covered Properties (82)
Neoantigen Identification, Manufacture, and Use
Application: 15/381,375 →
Publication: US 2017/0199961
Neoantigen Identification, Manufacture, and Use
Application: 15/466,729 →
Publication: US 2017/0212984
Neoantigen Identification, Manufacture, and Use
Application: 16/001,569 →
Publication: US 2019/0065675
Neoantigen identification, manufacture, and use
Application: 16/040,409 →
Publication: US 2018/0330055
Neoantigen Identification Using Hotspots
Application: 16/403,331 →
Publication: US 2019/0279742
Viral Delivery of Neoantigens
Application: 16/463,787 →
Publication: US 2020/0010849
Neoantigen Identification, Manufacture, and Use
Application: 16/606,577 →
Publication: US 2021/0113673
Alphavirus Neoantigen Vectors
Application: 16/612,352 →
Publication: US 2020/0197500
Neoantigen Identification, Manufacture, and Use
Application: 16/619,652 →
Publication: US 2020/0105377
Antigen-Binding Proteins Targeting Shared Antigens
Application: 16/639,073 →
Publication: US 2021/0147550
Neoantigen Identification for T-Cell Therapy
Application: 16/644,934 →
Publication: US 2020/0363414
Reducing Junction Epitope Presentation for Neoantigens
Application: 16/766,627 →
Publication: US 2021/0011026
Antigen-Binding Proteins Targeting Shared Antigens
Application: 16/958,615 →
Publication: US 2021/0061914
Neoantigen Identification with Pan-Allele Models
Application: 16/975,823 →
Publication: US 2020/0411135
Immune Checkpoint Inhibitor Co-Expression Vectors
Application: 17/058,113 →
Publication: US 2021/0213122
Shared Antigens
Application: 17/058,128 →
Publication: US 2021/0196806
Neoantigen Identification, Manufacture, and Use
Application: 17/101,518 →
Publication: US 2021/0098077
Neoantigen Identification, Manufacture, and Use
Application: 17/101,522 →
Publication: US 2021/0166784
Neoantigen Identification, Manufacture, and Use
Application: 62/268,333 →
Neoantigen Identification, Manufacture, and Use
Application: 62/317,823 →
Neoantigen Identification, Manufacture, and Use
Application: 62/379,986 →
Neoantigen Identification, Manufacture, and Use
Application: 62/394,074 →
Neoantigen Identification, Manufacture, and Use
Application: 62/425,995 →
Viral Delivery of Neoantigens
Application: 62/425,996 →
Viral Delivery of Neoantigens
Application: 62/435,266 →
Neoantigen Identification, Manufacture, and Use
Application: 62/487,469 →
Viral Delivery of Neoantigens
Application: 62/503,196 →
Alphavirus Neoantigen Vectors
Application: 62/503,283 →
Neoantigen Identification, Manufacture, and Use
Application: 62/517,786 →
Alphavirus Neoantigen Vectors
Application: 62/523,201 →
Viral Delivery of Neoantigens
Application: 62/523,212 →
Antigen-Binding Proteins Targeting Shared Antigens
Application: 62/547,146 →
Neoantigen Identification, Manufacture, and Use
Application: 62/554,286 →
Neoantigen Identification, Manufacture, and Use
Application: 62/570,569 →
Neoantigen identification, manufacture, and use
Application: 62/579,734 →
Antigen-Binding Proteins Targeting Shared Antigens
Application: 62/581,368 →
Neoantigen identification, manufacture, and use
Application: 62/590,045 →
Alphavirus Neoantigen Vectors
Application: 62/590,163 →
Antigen-Binding Proteins Targeting Shared Antigens
Application: 62/611,403 →
Neoantigen Identification, Manufacture, and Use
Application: 62/636,061 →
Neoantigen Identification, Manufacture, and Use
Application: 62/644,191 →
Shared Neoantigens
Application: 62/675,559 →
Immune Checkpoint Inhibitor Co-expression Vectors
Application: 62/675,624 →
Shared Antigen Compositions and Related Methods
Application: 62/675,649 →
Neoantigen Identification, Manufacture, and Use
Application: 62/703,197 →
Antigen-Binding Proteins Targeting Shared Antigens
Application: 62/719,565 →
Antigen-Binding Proteins Targeting Shared Antigens
Application: 62/756,508 →
Alphavirus Neoantigen Vectors and Interferon Inhibitors
Application: 62/756,980 →
Multispecific Binding Proteins
Application: 62/798,450 →
Multispecific Binding Proteins
Application: 62/807,702 →
Antigen-Binding Proteins Targeting Shared Antigens
Application: 62/808,775 →
Identification of Neoantigens Presented by MHC Class II Alleles for T-cell Therapy
Application: 62/814,801 →
Identification of Neoantigens with MHC Class II Model
Application: 62/826,822 →
Modified Adenoviruses
Application: 62/854,865 →
HIV Antigens and MHC Complexes
Application: 62/869,877 →
Antigen-Binding Proteins Targeting Shared Antigens
Application: 62/869,923 →
Multispecific Binding Proteins
Application: 62/869,992 →
Antigen Binding Proteins Targeting Shared Neoantigens
Application: 62/930,374 →
Shared Neoantigen Vaccines
Application: 62/930,460 →
Antigen-Binding Proteins Targeting Shared Neoantigens
Application: 62/936,303 →
Durable Vaccination
Application: 62/946,947 →
Neoantigen Vaccines
Application: 62/946,956 →
Neoantigen Vaccines
Application: 62/959,798 →
Cell-Free Dna Monitoring
Application: 62/959,805 →
Antigen-Binding Proteins Targeting Kklc-1 Shared Antigen
Application: 62/979,271 →
Infectious Disease Antigens and Vaccines
Application: 63/005,160 →
Capping Compounds, Compositions and Methods of Use Thereof
Application: 63/013,456 →
Antigen-Encoding Cassettes
Application: 63/013,466 →
Capping Compounds, Compositions and Methods of Use Thereof
Application: 63/020,473 →
Sars-Cov-2 Vaccines
Application: 63/027,283 →
HIV Antigens and MHC Complexes
Application: 63/029,981 →
Antigen-Binding Proteins Targeting Shared Neoantigens
Application: 63/030,774 →
Sars-Cov-2 Vaccines
Application: 63/047,789 →
Neoantigen Vaccine Therapy
Application: 63/051,227 →
Engineered Multi-Specific Antibodies and Related Methods of Use and Manufacture
Application: 63/058,461 →
Multiepitope Vaccine Cassettes
Application: 63/062,268 →
Antigen-Binding Proteins and Related Methods of Use
Application: 63/092,457 →
Homologous Adenoviral Vaccination
Application: 63/121,164 →
Compositions and Methods of Use Thereof
Application: 63/121,603 →
Multi-Specific Antibodies and Methods of Use
Application: 63/137,702 →
Sars-Cov-2 Vaccines
Application: 63/139,292 →
Modified Alphavirus Vectors
Application: 63/139,297 →
Related Assignments (25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Sep 21, 2016
From: YELENSKY, ROMAN; DERTI, ADNAN; BULIK-SILLIVAN, BRENDAN
To: GRITSTONE ONCOLOGY, INC.
Reel/Frame 039819/0930 →
Assignment of Assignor's Interest Sep 21, 2016
From: YELENSKY, ROMAN; DERTI, ADNAN; BULIK-SILLIVAN, BRENDAN
To: GRITSTONE ONCOLOGY, INC.
Reel/Frame 039819/0627 →
Assignment of Assignor's Interest Sep 21, 2016
From: YELENSKY, ROMAN; DERTI, ADNAN; BULIK-SILLIVAN, BRENDAN
To: GRITSTONE ONCOLOGY, INC.
Reel/Frame 039819/0647 →
Corrective Assignment to Correct the Name of Third Inventor Previously Recorded on Reel 039819 Frame 0930. Assignor(S) Hereby Confirms the Assignment. Nov 22, 2016
From: YELENSKY, ROMAN; DERTI, ADNAN; BULIK-SULLIVAN, BRENDAN
To: GRITSTONE ONCOLOGY, INC.
Reel/Frame 040665/0413 →
Corrective Assignment to Correct the Name of the Third Inventor Previously Recorded on Reel 039819 Frame 0647. Assignor(S) Hereby Confirms the Assignment. Nov 22, 2016
From: YELENSKY, ROMAN; DERTI, ADNAN; BULIK-SULLIVAN, BRENDAN
To: GRITSTONE ONCOLOGY, INC.
Reel/Frame 040665/0424 →
Assignment of Assignor's Interest Dec 1, 2016
From: YELENSKY, ROMAN; DERTI, ADNAN; BULIK-SULLIVAN, BRENDAN; BUSHY, JENNIFER
To: GRITSTONE ONCOLOGY, INC.
Reel/Frame 040485/0679 →
Corrective Assignment to Correct the Third Inventors Name Previously Recorded on Reel 039819 Frame 0627. Assignor(S) Hereby Confirms the Correct Spelling Is Brendan Bulik-Sullivan. Jan 11, 2017
From: YELENSKY, ROMAN; DERTI, ADNAN; BULIK-SULLIVAN, BRENDAN
To: GRITSTONE ONCOLOGY, INC.
Reel/Frame 041330/0039 →
Corrective Assignment to Correct the Fourth Inventors Name Previously Recorded on Reel 040485 Frame 0679. Assignor(S) Hereby Confirms the Correct Spelling Is Jennifer Busby. Jan 11, 2017
From: YELENSKY, ROMAN; DERTI, ADNAN; BULIK-SULLIVAN, BRENDAN; BUSBY, JENNIFER
To: GRITSTONE ONCOLOGY, INC.
Reel/Frame 041329/0909 →
Assignment of Assignor's Interest May 20, 2017
From: YELENSKY, ROMAN; DERTI, ADNAN; BULIK-SULLIVAN, BRENDAN; BUSBY, JENNIFER
To: GRITSTONE ONCOLOGY, INC.
Reel/Frame 042445/0268 →
Assignment of Assignor's Interest May 20, 2017
From: YELENSKY, ROMAN; DERTI, ADNAN; BULIK-SULLIVAN, B; BUSBY, JENNIFER
To: GRITSTONE ONCOLOGY, INC.
Reel/Frame 042445/0264 →
Assignment of Assignor's Interest Aug 18, 2017
From: JOOSS, KARIN; BLAIR, WADE; YELENSKY, ROMAN; DERTI, ADNAN
To: GRITSTONE ONCOLOGY, INC.
Reel/Frame 043335/0054 →
Assignment of Assignor's Interest Aug 29, 2017
From: JOOSS, KARIN; BLAIR, WADE; YELENSKY, ROMAN; DERTI, ADNAN
To: GRITSTONE ONCOLOGY, INC.
Reel/Frame 043440/0492 →
Assignment of Assignor's Interest Mar 29, 2018
From: YELENSKY, ROMAN; DETRI, ADNAN; BULIK-SULLIVAN, BRENDAN
To: GRITSTONE ONCOLOGY, INC.
Reel/Frame 045382/0486 →
Assignment of Assignor's Interest Jul 24, 2018
From: YELENSKY, ROMAN; DERTI, ADNAN; BULIK-SULLIVAN, BRENDAN; BUSBY, JENNIFER
To: GRITSTONE ONCOLOGY, INC.
Reel/Frame 046447/0380 →
Assignment of Assignor's Interest Sep 19, 2018
From: YELENSKY, ROMAN; DERTI, ADNAN; BULIK-SULLIVAN, BRENDAN; BUSBY, JENNIFER
To: GRITSTONE ONCOLOGY, INC.
Reel/Frame 046915/0887 →
Assignment of Assignor's Interest Oct 9, 2019
From: BULIK-SULLIVAN, BRENDAN; BOUCHER, THOMAS FRANCIS; YELENSKY, ROMAN
To: GRITSTONE ONCOLOGY, INC.
Reel/Frame 050666/0755 →
Assignment of Assignor's Interest Dec 11, 2019
From: BOUCHER, THOMAS FRANCIS; BULIK-SULLIVAN, BRENDAN; BUSBY, JENNIFER; YELENSKY, ROMAN
To: GRITSTONE ONCOLOGY, INC.
Reel/Frame 051252/0047 →
Assignment of Assignor's Interest Dec 11, 2019
From: BULIK-SULLIVAN, BRENDAN; YELENSKY, ROMAN; BUSBY, JENNIFER; DERTI, ADNAN
To: GRITSTONE ONCOLOGY, INC.
Reel/Frame 051252/0006 →
Assignment of Assignor's Interest Jan 17, 2020
From: BLAIR, WADE; BULIK-SULLIVAN, BRENDAN; BUSBY, JENNIFER; DERTI, ADNAN
To: GRITSTONE ONCOLOGY, INC.
Reel/Frame 051550/0648 →
Assignment of Assignor's Interest Jan 17, 2020
From: BLAIR, WADE; JOOSS, KARIN; RAPPAPORT, AMY RACHEL; SCALLAN, CIARAN DANIEL
To: GRITSTONE ONCOLOGY, INC.
Reel/Frame 051550/0532 →
Assignment of Assignor's Interest Mar 18, 2020
From: JOOSS, KARIN; BLAIR, WADE; BULIK-SULLIVAN, BRENDAN; BUSBY, JENNIFER
To: GRITSTONE ONCOLOGY, INC.
Reel/Frame 052152/0687 →
Assignment of Assignor's Interest Jul 14, 2020
From: JOOSS, KARIN; BLAIR, WADE; BULIK-SULLIVAN, BRENDAN; BUSBY, MICHELE ANNE
To: GRITSTONE ONCOLOGY, INC.
Reel/Frame 053207/0754 →
Assignment of Assignor's Interest Jul 20, 2020
From: BULIK-SULLIVAN, BRENDAN; BOUCHER, THOMAS FRANCIS; YELENSKY, ROMAN; BUSBY, JENNIFER
To: GRITSTONE ONCOLOGY, INC.
Reel/Frame 053251/0051 →
Assignment of Assignor's Interest Sep 24, 2020
From: BOUCHER, AMANDA J.L.; BULIK-SULLIVAN, BRENDAN; BUSBY, JENNIFER; SKOBERNE, MOJCA
To: GRITSTONE ONCOLOGY, INC.
Reel/Frame 053870/0337 →
Assignment of Assignor's Interest Nov 25, 2020
From: YELENSKY, ROMAN; DERTI, ADNAN; BULIK-SULLIVAN, BRENDAN; BUSBY, JENNIFER
To: GRITSTONE ONCOLOGY, INC.
Reel/Frame 054467/0601 →